Your browser doesn't support javascript.
loading
Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP).
Pallapothu, Manoj R; Quintana Mariñez, Maria G; Chakkera, Mohana; Ravi, Niriksha; Ramaraju, Rajita; Vats, Aastha; Nair, Athira R; Bandhu, Atithi K; Koirala, Divya; Mohammed, Lubna.
Afiliación
  • Pallapothu MR; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Quintana Mariñez MG; Neurology, Pontiac General Hospital, Pontiac, USA.
  • Chakkera M; Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Ravi N; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Ramaraju R; Internal Medicine and Neurology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Vats A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Nair AR; General Practice, Lady Hardinge Medical College, New Delhi, IND.
  • Bandhu AK; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Koirala D; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  • Mohammed L; Internal Medicine, Pontiac General Hospital, Pontiac, USA.
Cureus ; 15(10): e46696, 2023 Oct.
Article en En | MEDLINE | ID: mdl-38021691
In this literature review, we will evaluate the effectiveness of OnabotulinumtoxinA (Botox) and anti-calcitonin gene-related peptide (anti-CGRP) in the treatment of migraine headaches. Both therapies are frequently prescribed for managing and preventing migraines and have received Food and Drug Administration (FDA) approval. The mechanism of action, side effects, compliance, cost-effectiveness, and migraine treatment provided by these two medicines were compared in the analysis of several studies. Many studies found that as Botox was administered by a doctor every three months and had fewer side effects than anti-CGRP, which is self-administered every month, it was more compliant than anti-CGRP. After examining the data, Botox is believed to be the most effective therapy. Although both therapies are efficient, this article compares them to determine which is the best management strategy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos